In the FTO obesity locus, which upstream regulator normally represses the enhancer controlling IRX3/IRX5 expression?

Question

BlackTom AI · Accepted Answer

ARID5B is a transcriptional repressor that binds the obesity-associated regulatory element in the FTO locus and normally suppresses the enhancer that drives IRX3 and IRX5 expression.

1. Relevant knowledge points and concepts
- The FTO obesity locus contains noncoding variants that alter a regulatory enhancer controlling the expression of the developmental transcription factors IRX3 and IRX5; increased IRX3/IRX5 expression shifts adipocyte precursors toward energy-storing white adipocytes.
- Upstream regulators (transcription factors) can repress or activate enhancers by binding DNA motifs; loss of a repressor or its binding increases enhancer activity and target gene expression.
- ARID5B (AT-rich interaction domain 5B) is a transcriptional regulator known to bind AT-rich sequences and act as a repressor at certain enhancers, including the FTO-associated enhancer.

2. Step-by-step reasoning
- The functional link established by genetic and molecular studies shows that the obesity-associated noncoding region in intron 1 of FTO acts as an enhancer for IRX3/IRX5.
- Investigations identified binding sites for ARID5B within this enhancer and demonstrated that ARID5B occupancy normally reduces enhancer activity.
- When ARID5B binding is disrupted (by risk allele or perturbation), repression is relieved, leading to increased IRX3/IRX5 expression and predisposition to adiposity.

3. Intermediate evidence steps
- Chromatin immunoprecipitation (ChIP) and reporter assays show ARID5B binding correlates with lower enhancer-driven reporter activity.
- Loss-of-function or diminished binding results in higher reporter expression and upregulation of IRX3/IRX5 in adipocyte models.

4. Why the correct answer is correct
- ARID5B directly represses the FTO-locus enhancer; this mechanistic role explains how changes at that site increase IRX3/IRX5 expression and influence adipocyte differentiation, linking genotype to phenotype.

5. Why other options are incorrect
- SORT1 and PCSK9 are genes involved in lipid metabolism but are not documented repressors of the FTO enhancer.
- FTO is the gene locus containing the enhancer but not the upstream repressor regulator.
- TCF21 is a transcription factor with roles in development but not identified as the repressive regulator of the IRX3/IRX5-controlling enhancer.

6. Conclusion
This evidence confirms ARID5B is the upstream regulator that normally represses the enhancer controlling IRX3/IRX5 expression, matching the provided answer: ARID5B.

In the FTO obesity locus, which upstream regulator normally represses the enhancer controlling IRX3/IRX5 expression?单项选择题

类似问题

True or false: repressible positive regulation occurs when the gene is transcribed in the presence of a specific small molecule?

True or false: inducible negative regulation occurs when the gene is not transcribed in the presence of a specific small molecule?

A deletion of the lacP (promoter) region in the lac operon would result in which of the following?

Which of the following event(s) need to happen for the glucocorticoid receptor to activate a gene?

A small effector molecule induces transcription. Which combination below is consistent with this idea?

For this question, pick one of the words or phrases in the parentheses and type it in the blank. In negative regulation, the regulatory protein is called a [ Select ] inducer repressor activator when it binds to DNA it [ Select ] blocks activates DNA transcription

Which of the follow are points of regulation in microorganisms?

更多留学生实用工具

智能学习助手

风格化写作助手

论文查重助手

文献引用助手

课堂转译助手

课堂笔记助手

Quiz搜索助手

学校历年真题

智能刷题助手

智能匹配练习

希望你的学习变得更简单